New combo aims to stop leukemia return in older patients
NCT ID NCT07463768
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding ivosidenib to oral azacitidine (Onureg) can help prevent acute myeloid leukemia (AML) from coming back in people over 55 who have a specific IDH1 mutation and are already in remission after chemotherapy. About 60 participants will take both pills daily until the disease returns or side effects become too much. The main goal is to see how many remain relapse-free after two years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CH côte Basque
Bayonne, 64109, France
-
CH de Perpignan
Perpignan, 66046, France
-
CHRU Nancy
Vandœuvre-lès-Nancy, 54500, France
-
CHU Angers
Angers, 49933, France
-
CHU Besançon
Besançon, 25030, France
-
CHU Grenoble
Grenoble, 38043, France
-
CHU Henri Mondor
Créteil, 94000, France
-
CHU de Limoges
Limoges, 87000, France
-
CHU de Nantes
Nantes, 44093, France
-
CHU de Nîmes - Institut de Cancérologie du Gard
Nîmes, 30029, France
-
CHU de TOULOUSE - IUCT ONCOPOLE
Toulouse, 31059, France
-
Centre Henri Becquerel
Rouen, 76038, France
-
Chru Bretonneau
Tours, 37044, France
-
Chru de Lille - Hopital Claude Huriez
Lille, 59037, France
-
Chu de Rennes - Hopital Pontchaillou
Rennes, 35033, France
-
Gustave Roussy
Villejuif, 94800, France
-
Hopital d'Instruction des Armées Percy
Clamart, 92140, France
-
Hôpital Haut-Lévêque
Pessac, 33604, France
-
Hôpital Lyon-Sud
Pierre-Bénite, 69310, France
-
Hôpital Saint Louis
Paris, 75010, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?